of Canada, Canada
of Canada, Canada

Time filter

Source Type

News Article | March 1, 2017
Site: www.marketwired.com

TORONTO, ONTARIO--(Marketwired - March 1, 2017) - The Empire Life Insurance Company (Empire Life) (TSX:EML.PR.A.) announced today it will make its specialty drug program a standard feature in all Group drug plans it offers. The specialty drug program, part of the Empire Life Actively Managed Drug Solutions portfolio, will be included in new customers' plans starting June 1, 2017. Current customers will join the program when their policies renew. Specialty drugs are high-cost prescription medications used to treat complex health conditions, such as cancer, rheumatoid arthritis, blood disorders, and multiple sclerosis. They often require special handling and administration. The specialty drug program will be available to all customers with a pay-direct drug card, in all provinces except Quebec. Empire Life is partnering with Express Scripts CanadaΓôç to deliver the specialty drug program, to help employers keep drug benefit costs low while providing employees with better options for managing complex health conditions. The specialty drug program provides personalized education and coaching, as well as dispensing of medication. The result is that employees: Chronic disease is on the rise in Canada1 and this means more medications are being charged to drug benefit plans. At the same time, new specialty drugs are coming to market in ever greater number. They can dramatically improve treatment and quality of life-and can be costly. According to the Express Scripts Canada 2015 Drug Trend Report, specialty drugs accounted for just 2% of the claims they processed in 2015, yet represented 30% of customers' drug spend overall. Express Scripts Canada predicts this will reach 42% of spend by 2020. (1) Public Health Agency of Canada. "Against the Growing Burden of Disease". www.ccgh-csih.ca/assets/Elmslie.pdf "New, high-cost drugs are beginning to put pressure on drug benefits, and our customers need solutions to keep their plans sustainable and competitive," said Steve Pong, senior vice-president, Group Solutions at Empire Life. "We are delighted to partner with Express Scripts Canada and bring their expertise to our customers. Express Scripts Canada is considered a premier provider of drug benefit management services, and they're making significant contributions when it comes to managing the high cost of drugs in Canada-as evidenced in a recent episode of CBC's The Fifth Estate." "Tackling cost head-on through cost shifting or cutting benefits is not the best solution for employers in the long run," said Michael Biskey, President, Express Scripts Canada. "For employers, the prescription drug benefit plan makes it possible to attract highly skilled employees, enhance engagement and productivity, and reduce absenteeism. For employees, it means better health for themselves and their families. Our innovative solution allows Empire Life to offer its customers the kind of holistic support and care they need when they need it." Established in 1923 and a subsidiary of E-L Financial Corporation Limited, Empire Life provides individual and group life and health insurance, investment and retirement products to Canadians. Our mission is to make it simple, fast and easy for Canadians to get the investment, insurance and group benefits coverage they need to build wealth, generate income, and achieve financial security. As of December 31, 2016 Empire Life had total assets under management of $16.1 billion. Follow Empire Life on Twitter @EmpireLife or visit www.empire.ca for more information. Express Scripts Canada transforms the way organizations and employees think about and participate in their drug benefit plan. Express Scripts Canada provides pharmacy services to thousands of Canadian patients. Through its proprietary consumer intelligence, clinical expertise, and patients-first approach, Express Scripts Canada promotes better health decisions for plan members, while managing and reducing drug benefit costs for plan sponsors. Express Scripts Canada is indirectly owned by Express Scripts Holding Company. For more information, visit www.express-scripts.ca.


An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to results published today in The Lancet. The vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year. [1] The vaccine, called rVSV-ZEBOV [2], was studied in a trial involving 11,841 people in Guinea during 2015. Among the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination [3]. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine. The trial was led by the World Health Organization, together with Guinea's Ministry of Health and other international partners. "While these compelling results come too late for those who lost their lives during West Africa's Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless," said Dr Marie-Paule Kieny, WHO's Assistant Director-General for Health Systems and Innovation, and the study's lead author [4]. The vaccine's manufacturer, Merck, Sharpe & Dohme, this year received Breakthrough Therapy Designation from the United States Food and Drug Administration and PRIME status from the European Medicines Agency, enabling faster regulatory review of the vaccine once it is submitted. Since Ebola virus was first identified in 1976, sporadic outbreaks have been reported in Africa. But the 2013-2016 West African Ebola outbreak, which resulted in more than 11,300 deaths, highlighted the need for a vaccine. The trial took place in the coastal region of Basse-Guinée, the area of Guinea still experiencing new Ebola cases when the trial started in 2015. The trial used an innovative design, a so-called "ring vaccination" approach - the same method used to eradicate small pox. When a new Ebola case was diagnosed, the research team traced all people who may have been in contact with that case within the previous 3 weeks, such as people who lived in the same household, were visited by the patient, or were in close contact with the patient, their clothes or linen, as well as certain "contacts of contacts". A total of 117 clusters (or "rings") were identified, each made up of an average of 80 people. Initially, rings were randomised to receive the vaccine either immediately or after a 3-week delay, and only adults over 18 years were offered the vaccine. After interim results were published showing the vaccine's efficacy, all rings were offered the vaccine immediately and the trial was also opened to children older than 6 years. In addition to showing high efficacy among those vaccinated, the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach (so-called "herd immunity"). However, the authors note that the trial was not designed to measure this effect, so more research will be needed. "Ebola left a devastating legacy in our country. We are proud that we have been able to contribute to developing a vaccine that will prevent other nations from enduring what we endured" said Dr KeÏta Sakoba, Coordinator of the Ebola Response and Director of the National Agency for Health Security in Guinea [4]. To assess safety, people who received the vaccine were observed for 30 minutes after vaccination, and at repeated home visits up to 12 weeks later. Approximately half reported mild symptoms soon after vaccination, including headache, fatigue and muscle pain but recovered within days without long-term effects. Two serious adverse events were judged to be related to vaccination (a febrile reaction and one anaphylaxis) and one was judged to be possibly related (influenza-like illness). All three recovered without any long term effects. It was not possible to collect biological samples from people who received the vaccine in order to analyse their immune response. Other studies are looking at the immune response to the vaccine including one conducted in parallel to the ring trial among frontline Ebola workers in Guinea. "This both historical and innovative trial was made possible thanks to exemplary international collaboration and coordination, the contribution of many experts worldwide, and strong local involvement," said Dr John-Arne Røttingen, Specialist Director at the Norwegian Institute of Public Health, and the chairman of the study steering group [4]. In January, GAVI, the Vaccine Alliance provided US$5 million to Merck towards the future procurement of the vaccine once it is approved, prequalified and recommended by WHO. As part of this agreement, Merck committed to ensure that 300,000 doses of the vaccine are available for emergency use in the interim, and to submit the vaccine for licensure by the end of 2017. Merck has also submitted the vaccine to WHO's Emergency Use and Assessment Listing procedure, a mechanism through which experimental vaccines, medicines and diagnostics can be made available for use prior to formal licensure. Additional studies are ongoing to provide more data on the safety of the vaccine in children and other vulnerable populations such as people with HIV. In case of Ebola flare-ups prior to approval, access to the vaccine is being made available through a procedure called "compassionate use" that enables use of the vaccine after informed consent. Merck and WHO's partners are working to compile data to support license applications. The rapid development of rVSV-EBOV contributed to the development of WHO's R&D Blueprint, a global strategy to fast-track the development of effective tests, vaccines and medicines during epidemics. Also published in The Lancet (embargo as above), is a phase 2 trial of a different Ebola vaccine candidate, the recombinant adenovirus type-5 Ebola vaccine. The trial was led by the Beijing Institute of Biotechnology and was conducted in Sierra Leone in 2015. It involved 500 healthy participants, followed for 6 months - 250 were given a high dose vaccine, 125 a low-dose and 125 a placebo. The study found that the vaccine was safe and induced an immune response that peaked at 28 days, but decreased during the six months post injection. One serious adverse event was reported, in an individual with a history of asthma. Further research on this vaccine is needed in order to assess its efficacy. The rVSV-ZEBOV trial is funded by WHO, with support from the Wellcome Trust, the United Kingdom Department for International Development, the Norwegian Ministry of Foreign Affairs to the Norwegian Institute of Public Health through the Research Council of Norway, the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre and Department of Foreign Affairs, Trade and Development and Médecins Sans Frontières. The trial team includes experts from The University of Bern, the University of Florida, the London School of Hygiene and Tropical Medicine, Public Health England, the European Mobile Laboratories among others. The trial was designed by a group of experts including the late Professor Donald A. Henderson of John Hopkins University, who led the WHO smallpox eradication effort by using the ring vaccination strategy. [1] http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61117-5/abstract [2] VSV-EBOV was developed by the Public Health Agency of Canada. The vaccine was licensed to NewLink Genetics, who in turn licensed it to Merck & Co. The vaccine works by replacing a gene from a harmless virus known as vesicular stomatitis virus (VSV) with a gene encoding an Ebola virus surface protein. The vaccine does not contain any live Ebola virus. Earlier trials have shown the vaccine to be protective in animals, and be safe and produce an immune response in humans. [3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus. [4] Quotes direct from authors and cannot be found in the text of the Article.


TORONTO, ON--(Marketwired - February 16, 2017) - The Canadian Centre for Aging and Brain Health Innovation (CC-ABHI) announced today the launch of its Researcher-Clinician Partnership Program (RCP2). This program is uniquely designed to greatly enhance the effectiveness of connecting point-of-care clinicians in the senior care sector with university-based researchers to collaboratively design, test and validate innovative products, services or health practices in aging and brain health in a real-world care setting. In total, up to CAD $2.4 million in funding will be available. RCP2 is seeking applicants with innovations that aim to find solutions for the following care priorities, of which the first three are aimed at older adults with dementia: "The Government of Canada is proud to support the Canadian Centre for Aging and Brain Health Innovation and its programs. These programs encourage partnerships to bring innovative new ideas and creative solutions in brain health and cognitive fitness to Canadians. Their work to improve the quality of life for those living with dementia, and for their caregivers, is a priority for our government," says the Honourable Jane Philpott, Canada's Minister of Health. "The collaborations being created through the Researcher-Clinician Partnership Program will help accelerate creative solutions in aging and brain health, and we are proud to support this initiative. Our government remains committed to finding new ways to continue to improve the quality of life for seniors in Ontario, and fostering innovative developments in brain health is an important part of that commitment," says the Honourable Reza Moridi, Ontario's Minister of Research, Innovation and Science. "The Researcher-Clinician Partnership Program will provide a significant opportunity for health professionals who are working collaboratively to secure the support needed to test, refine and validate their innovative solutions with the aging population in a real-world setting," says Dr. William Reichman, President and Chief Executive Officer of Baycrest Health Sciences, which leads CC-ABHI. Health professionals applying for the program must be part of a team that includes at least one researcher and one clinician. Teams may also include additional clinicians, researchers, educators, industry partners and end-users located worldwide. Applicants must demonstrate that their product, service or health practice is at an advanced stage of development as defined in the Call for Innovations. Teams must demonstrate that the proposed solution has the potential to be scaled across multiple organizations in North America and is ready for pilot testing and evaluation. CC-ABHI will support project costs that are directly associated with the trial of an innovative solution, to a maximum of CAD $600,000 per project. CC-ABHI's funding will be provided directly to the host institution employing the principal Investigators of the qualifying projects. All projects must be completed within a 12 to 18 month period. Eligible applicants must submit an Expression of Interest by 5 p.m. EST on March 30, 2017. Shortlisted applicants will then be invited to complete a full application form, which must be submitted by 5 p.m. EST on May 25, 2017. The complete eligibility requirements, selection criteria and additional information about the program are available on the CC-ABHI website. Funding for the Researcher-Clinician Partnership Program is provided by the Government of Canada through the Public Health Agency of Canada, by the Government of Ontario through the Ministry of Research, Innovation and Science, and by the Baycrest Foundation. The Canadian Centre for Aging and Brain Health Innovation (CC-ABHI) is a solution accelerator for the aging and brain health sector, providing funding and support to innovators for the development, testing, and dissemination of new ideas and technologies that address unmet brain health and seniors' care needs. Established in 2015, it is the result of the largest investment in brain health and aging in Canadian history. CC-ABHI is a unique collaboration of health care, science, industry, not-for-profit and government partners whose aim is to help improve quality of life for the world's aging population, allowing older adults to age safely in the setting of their choice while maintaining their cognitive, emotional, and physical well-being. For more information on CC-ABHI, please visit: www.ccabhi.com. Baycrest Health Sciences is a global leader in geriatric residential living, healthcare, research, innovation and education, with a special focus on brain health and aging. Fully affiliated with the University of Toronto, Baycrest provides excellent care for older adults combined with an extensive clinical training program for the next generation of healthcare professionals and one of the world's top research institutes in cognitive neuroscience, the Rotman Research Institute. Baycrest is home to the federally and provincially-funded Canadian Centre for Aging and Brain Health Innovation, a solution accelerator focused on driving innovation in the aging and brain health sector, and is the developer of Cogniciti -- a free online memory assessment for Canadians 40+ who are concerned about their memory. Through its dedicated centres, the organization offers unmatched global knowledge exchange and commercialization capacity. Founded in 1918 as the Jewish Home for Aged, Baycrest continues to embrace the long-standing tradition of all great Jewish healthcare institutions to improve the well-being of people in their local communities and around the globe. For more information please visit: www.baycrest.org.


Pelletier C.,Public Health Agency of Canada
Chronic diseases and injuries in Canada | Year: 2012

"Diabetes in Canada: facts and figures from a public health perspective" is the first comprehensive diabetes surveillance report published by the Public Health Agency of Canada. The report aims to support public health professionals and organizations in developing effective, evidence-based public health policies and programs to prevent and manage diabetes and its complications. The report, developed in collaboration with provincial and territorial governments, the Canadian Diabetes Association, Juvenile Diabetes Research Foundation, CNIB, Health Canada and the academic community, uses data from national health surveys and vital statistics, as well as population-based administrative data from the Canadian Chronic Disease Surveillance System (CCDSS). For the first time, the CCDSS contains data from all 13 Canadian jurisdictions. Using CCDSS data representing cases of diagnosed diabetes among Canadians aged one year and older, Diabetes in Canada presents prevalence and incidence national rates from the fiscal year 2008/2009 and national trends from 1998/1999 onwards. The report also outlines sub-populations at higher risk, ways of reducing the risks of developing the disease and its complications, and estimates of related economic costs. In addition, it contains sections on specific populations, including children and youth and First Nations, Inuit and Métis populations.


Four authoritative reviews of active smoking and breast cancer have been published since 2000, but only one considered data after 2002 and conclusions varied. Three reviews of secondhand smoke (SHS) and breast cancer (2004-2006) each came to different conclusions. With 30 new studies since 2002, further review was deemed desirable. An Expert Panel was convened by four Canadian agencies, the Ontario Tobacco Research Unit, the Public Health Agency of Canada, Physicians for a Smoke-Free Canada and the Canadian Partnership Against Cancer to comprehensively examine the weight of evidence from epidemiological and toxicological studies and understanding of biological mechanisms regarding the relationship between tobacco smoke and breast cancer. This article summarises the panel's full report (http://www.otru.org/pdf/special/expert_panel_tobacco_breast_cancer.pdf). There are 20 known or suspected mammary carcinogens in tobacco smoke, and recognised biological mechanisms that explain how exposure to these carcinogens could lead to breast cancer. Results from the nine cohort studies reporting exposure metrics more detailed than ever/never and ex/current smoker show that early age of smoking commencement, higher pack-years and longer duration of smoking increase breast cancer risk 15% to 40%. Three meta-analyses report 35% to 50% increases in breast cancer risk for long-term smokers with N-acetyltransferase 2 gene (NAT2) slow acetylation genotypes. The active smoking evidence bolsters support for three meta-analyses that each reported about a 65% increase in premenopausal breast cancer risk among never smokers exposed to SHS. The Panel concluded that: 1) the association between active smoking and breast cancer is consistent with causality and 2) the association between SHS and breast cancer among younger, primarily premenopausal women who have never smoked is consistent with causality.


Ulanova M.,Lakehead University | Tsang R.S.W.,Public Health Agency of Canada
The Lancet Infectious Diseases | Year: 2014

Haemophilus influenzae, particularly H influenzae serotype b (Hib), is an important pathogen that causes serious diseases like meningitis and septicaemia. Since the introduction of Hib conjugate vaccines in the 1990s, the epidemiology of invasive H influenzae disease has changed substantially, with most infections now caused by non-Hib strains. We discuss the importance of H influenzae serotype a (Hia) as a cause of serious morbidity and mortality and its global epidemiology, clinical presentation, microbiology, immunology, prevention, and control. Much like Hib, the capsule of Hia is an important virulence factor contributing to the development of invasive disease. Molecular typing of Hia has identified distinct clonal groups, with some linked to severe disease and high case-fatality rates. Similarities between Hia and Hib capsules, their clinical presentation, and immunology of infection suggest that a bivalent Hia-Hib capsular polysaccharide-protein conjugate vaccine could offer protection against these two important serotypes of H influenzae. © 2014 Elsevier Ltd.


Chang V.C.,Public Health Agency of Canada | Do M.T.,Public Health Agency of Canada
American Journal of Epidemiology | Year: 2015

Despite extensive literature on falls among seniors, little is known about gender-specific risk factors. To determine the prevalence of falls by gender and sociodemographic, lifestyle/behavioral, and medical factors, we conducted a cross-sectional study in a nationally representative sample of Canadian adults who were 65 years of age or older (n = 14,881) from the Canadian Community Health Survey-Healthy Aging (2008-2009). Logistic regression models were applied to investigate gender-specific associations between potential risk factors and falls. In men, stroke (odds ratio (OR) = 1.91), nutritional risk (OR = 1.86), post-secondary school degree (OR = 1.68), eye disorder (OR = 1.35), widowed/separated/divorced marital status (OR = 1.28), and arthritis (OR = 1.27) were independently associated with significantly higher odds of falls. In women, significant independent correlates of falls included stroke (OR = 1.53), age of 85 years or older (OR = 1.51), nutritional risk (OR = 1.39), consumption of at least 1 alcoholic drink per week (OR = 1.39), use of 5 or more medications (OR = 1.36), arthritis (OR = 1.36), diabetes (OR = 1.31), and osteoporosis (OR = 1.22). Higher physical activity levels were protective in both genders, and higher household income was protective in women. Gender should be considered when planning fall prevention strategies. © 2015 The Author.


Robinson C.A.,Public Health Agency of Canada
Chronic diseases and injuries in Canada | Year: 2011

Despite high rates of undiagnosed diabetes and prediabetes, suitable risk assessment tools for estimating personal diabetes risk in Canada are currently lacking. We conducted a cross-sectional screening study that evaluated the accuracy and discrimination of the new Canadian Diabetes Risk Assessment Questionnaire (CANRISK) for detecting diabetes and prediabetes (dysglycemia) in 6223 adults of various ethnicities. All participants had their glycemic status confirmed with the oral glucose tolerance test (OGTT). We developed electronic and paper-based CANRISK scores using logistic regression, and then validated them against reference standard blood tests using test-set methods. We used area under the curve (AUC) summary statistics from receiver operating characteristic (ROC) analyses to compare CANRISK with other alternative risk-scoring models in terms of their ability to discern true dysglycemia. The AUC for electronic and paper-based CANRISK scores were 0.75 (95% CI: 0.73-0.78) and 0.75 (95% CI: 0.73-0.78) respectively, as compared with 0.66 (95% CI: 0.63-0.69) for the Finnish FINDRISC score and 0.69 (95% CI: 0.66-0.72) for a simple Obesity model that included age, BMI, waist circumference and sex. CANRISK is a statistically valid tool that may be suitable for assessing diabetes risk in Canada's multi-ethnic population. CANRISK was significantly more accurate than both the FINDRISC score and the simple Obesity model.


News Article | November 17, 2016
Site: www.eurekalert.org

A single bout of sleep apnea impacts the human body's ability to regulate blood pressure. In a recent study measuring the impact of simulated sleep apnea on humans, researchers at UBC's Okanagan campus found that just six hours of the fluctuating oxygen levels associated with sleep apnea can begin to deteriorate a person's circulatory system. Sleep apnea is a condition where breathing repeatedly stops and starts during sleep. The condition can result in frequent periods of decreased oxygen levels in the body, known as intermittent hypoxia. "While it is well established that sleep apnea is linked to high blood pressure, our study shows this condition has an impact on the cardiovascular system that can begin within a single day," says Glen Foster, an assistant professor of health and exercise science. "After just six hours of fluctuating oxygen levels, similar to what happens with sleep apnea, the body's ability to regulate blood pressure is impaired. "These changes occurred almost immediately in healthy young adults who were not experiencing the cumulative effects years of sleep apnea could bring about." As part of his study, Foster examined the impact of intermittent hypoxia on the cardiovascular system in 10 healthy young adults. Study participants wore a ventilating mask for six hours and oxygen levels were altered to mimic sleep apnea symptoms. The study found that sleep apnea compromised the function of a person's baroreceptors--biological sensors that regulate blood pressure. It also found damaging blood flow patterns in the legs, which over time could impact vascular health. "These findings suggest that interventions for people suffering sleep apnea should occur as soon as the condition is diagnosed," adds Foster. According to the Public Health Agency of Canada, 5.4 million Canadians are either diagnosed with or at high risk for sleep apnea. Foster's research was recently published in the American Journal of Physiology.


News Article | March 3, 2017
Site: www.PR.com

Receive press releases from Multi-Channel Marketing Solution by SimplyCast.com: By Email SimplyCast revealed its new communication platform during its unveiling event, February 23. EmergHub is an all-in-one platform consisting of 24 modules that help with communication before, during, and after emergency events. EmergHub was funded through the Build in Canada Innovation program and piloted by the Public Health Agency of Canada and the Department of Health and Wellness in Nova Scotia. Dartmouth, Canada, March 03, 2017 --( EmergHub incorporates both the original SimplyCast applications as well as nine other modules that are geared toward making emergency communication processes safer and more efficient. EmergHub is the world’s first application with a common operating picture showing local areas and their interaction with emergency messages. It is the first technology to connect all stakeholders in an emergency situation by using an all-in-one platform for communications. EmergHub has the capability to provide prompt situational awareness and provides consistent and effective communication by laying out the common operating picture in a simple and intuitive dashboard that updates in real-time. The modules created for EmergHub include the capability to send out mass alerts, recall responders, initiate an instant teleconference by dialing out to participants’ phones, and manage the event from a single, web-based portal. The EmergHub platform was developed with funding from Public Service and Procurement Canada’s (PSPC) Build in Canada Innovation Program (BCIP). The Nova Scotia Department of Health and Wellness then signed on to pilot the technology. “On behalf of SimplyCast, I want to extend our sincere gratitude to Public Service and Procurement Canada and the Nova Scotia Department of Health and Wellness for their contribution and participation in the development and piloting of EmergHub,” said Saeed El-Darahali, President and CEO of SimplyCast. “We have built an innovative communication platform that will help improve emergency communication worldwide and it was built 100 percent here in Canada.” The EmergHub technology and all of the tools required are available in one centralized platform. By having the ability to share information with a common operating picture, efficiency is greatly increased and essential time is saved, especially during crisis situations. About SimplyCast SimplyCast is a leading provider of interactive and multi-channel communication software for organizations worldwide. Providing both emergency and non-emergency communication technology, SimplyCast offers 24 communication tools and channels to help organizations maximize their efficiency. The company’s 360 Customer Flow Communication Platform is a feature-rich solution combining marketing automation, inbound marketing, and interactive communication. With customers in over 175 countries, including many of the most recognized brand names around the globe in retail, non-profit and hospitality industries, SimplyCast provides organizations the ability to effectively reach customers on their preferred mode of communication. For more information, contact: Alissa MacDougall alissa.macdougall@simplycast.com 866-323-6572 ext. 1403 www.simplycast.com Dartmouth, Canada, March 03, 2017 --( PR.com )-- SimplyCast, a leader in communication automation launched their new emergency communication platform, EmergHub, on February 23 at their unveiling event at the Halifax Marriot Harbourfront Hotel. The invite-only event had close to 700 attendees who celebrated the company’s recent achievements.EmergHub incorporates both the original SimplyCast applications as well as nine other modules that are geared toward making emergency communication processes safer and more efficient.EmergHub is the world’s first application with a common operating picture showing local areas and their interaction with emergency messages. It is the first technology to connect all stakeholders in an emergency situation by using an all-in-one platform for communications.EmergHub has the capability to provide prompt situational awareness and provides consistent and effective communication by laying out the common operating picture in a simple and intuitive dashboard that updates in real-time.The modules created for EmergHub include the capability to send out mass alerts, recall responders, initiate an instant teleconference by dialing out to participants’ phones, and manage the event from a single, web-based portal.The EmergHub platform was developed with funding from Public Service and Procurement Canada’s (PSPC) Build in Canada Innovation Program (BCIP). The Nova Scotia Department of Health and Wellness then signed on to pilot the technology.“On behalf of SimplyCast, I want to extend our sincere gratitude to Public Service and Procurement Canada and the Nova Scotia Department of Health and Wellness for their contribution and participation in the development and piloting of EmergHub,” said Saeed El-Darahali, President and CEO of SimplyCast. “We have built an innovative communication platform that will help improve emergency communication worldwide and it was built 100 percent here in Canada.”The EmergHub technology and all of the tools required are available in one centralized platform. By having the ability to share information with a common operating picture, efficiency is greatly increased and essential time is saved, especially during crisis situations.About SimplyCastSimplyCast is a leading provider of interactive and multi-channel communication software for organizations worldwide. Providing both emergency and non-emergency communication technology, SimplyCast offers 24 communication tools and channels to help organizations maximize their efficiency. The company’s 360 Customer Flow Communication Platform is a feature-rich solution combining marketing automation, inbound marketing, and interactive communication. With customers in over 175 countries, including many of the most recognized brand names around the globe in retail, non-profit and hospitality industries, SimplyCast provides organizations the ability to effectively reach customers on their preferred mode of communication.For more information, contact:Alissa MacDougallalissa.macdougall@simplycast.com866-323-6572 ext. 1403www.simplycast.com Click here to view the list of recent Press Releases from Multi-Channel Marketing Solution by SimplyCast.com

Loading Public Health Agency of Canada collaborators
Loading Public Health Agency of Canada collaborators